Immunosuppression After Pancreas Transplantation
During the past two decades, the results of clinical pancreas transplantation have improved considerably. Most pancreas transplantations are still performed as simultaneous pancreas/kidney transplantation (SPK) in patients with type I diabetes and end-stage nephropathy. Rejection of the pancreas graft and/or of the kidney in the case of SPK is still a major problem and requires potent immunosuppressive drugs. These drugs are associated with a widespread suppression of responsiveness of the immune system and numerous side effects, including susceptibility to infection and cancer. Many experimental models exist in large and small animals with the aim to overcome these problems and to induce long-term graft acceptance. In this chapter, we will elucidate the data from different immunosuppression protocols from the past few years to compare their potency in preventing rejection after pancreas transplantation in rats.
KeywordsCyclosporin Hyperglycemia Amylase Rapamycin Allo
Unable to display preview. Download preview PDF.
- 3.Klempnauer J, Wagner E, Wonigeit K, Pichlmayr R (1983) Pancreas and kidney allograft rejection responds differently to cyclosporin immunosuppression. Transplant Proc 15 [Suppl 1]:3001–3003Google Scholar
- 4.Timmermann W, Schang T, Thiede A (1985) The effect of temporary cyclosporin A treatment on the endocrine function of pancreaticoduodenal allografts in the rat. In: Thiede A, Deltz E, Engemann R, Hamelmann H (eds) Microsurgical models in rats for transplantation research. Springer, Berlin Heidelberg New York, pp 177–181CrossRefGoogle Scholar